Forbion Secures $2.6 Billion To Expand European Biotech Investment
· Business · Wall Street Journal, Nikkei Asia
The venture capital firm Forbion has successfully raised $2.6 billion to bolster the European biotechnology sector. This capital injection is intended to support the growth and development of emerging biotech companies across the region. The fundraising effort reflects a continued interest in life sciences and medical innovation within Europe. The firm plans to deploy these funds to accelerate research and commercialization efforts for promising startups.
Why it matters
This significant influx of capital provides critical support for European biotech innovation, potentially accelerating the development of new medical treatments and technologies.
Read the original report — Wall Street Journal
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.